Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Abraxane nab-paclitaxel: Phase III started

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Taiho Pharmaceutical Co. Ltd., Tokyo, Japan Product: Abraxane nab-paclitaxel (ABI-007) Business: Cancer Molecular target: Tubulin Description: Albumin stabilized nanoparticle …

    Published on 5/5/2014
  • Abraxane nab-paclitaxel: Phase III started

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Taiho Pharmaceutical Co. Ltd., Tokyo, Japan Product: Abraxane nab-paclitaxel (ABI-007) Business: Cancer Molecular target: Tubulin Description: Albumin stabilized nanoparticle …

    Published on 5/5/2014
  • ACH-3102: Phase II started

    Achillion Pharmaceuticals Inc. (NASDAQ:ACHN), New Haven, Conn. Product: ACH-3102 Business: Infectious Molecular target: HCV NS5A protein Description: Pan-genotypic, second-generation HCV NS5A protein inhibitor …

    Published on 5/5/2014
  • ACH-3422: Phase I started

    Achillion Pharmaceuticals Inc. (NASDAQ:ACHN), New Haven, Conn. Product: ACH-3422 Business: Infectious Molecular target: HCV NS5B polymerase Description: Small molecule nucleotide prodrug inhibitor of HCV NS5B polymerase…

    Published on 5/5/2014
  • Bavituximab: Phase Ib started

    Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM), Tustin, Calif. Product: Bavituximab (3G4) Business: Cancer Molecular target: Phosphatidylserine Description: Chimeric mAb against phosphatidylserine Indication: Treat …

    Published on 5/5/2014
  • Coltuximab ravtansine: Development discontinued

    ImmunoGen Inc. (NASDAQ:IMGN), Waltham, Mass. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Coltuximab ravtansine (SAR3419) Business: Cancer Molecular target: CD19 Description: Humanized CD19 mAb linked to …

    Published on 5/5/2014
  • CV-301: Phase II started

    Bavarian Nordic A/S (CSE:BAVA), Kvistgaard, Denmark Product: CV-301, CVAC-301 (formerly Panvac) Business: Cancer Molecular target: Carcinoembryonic antigen (CEA); Mucin 1 (MUC1) (CD227) Description: Vaccine targeting …

    Published on 5/5/2014
  • CVac: Phase II started

    Prima BioMed Ltd. (ASX:PRR; NASDAQ:PBMD), Sydney, Australia Product: CVac Business: Cancer Molecular target: Mucin 1 (MUC1) (CD227) Description: Ex vivo cancer vaccine using a patient's own dendritic cells primed with …

    Published on 5/5/2014
  • Dalvance dalbavancin: Phase IIIb started

    Durata Therapeutics Inc. (NASDAQ:DRTX), Chicago, Ill. Product: Dalvance dalbavancin (RQ-00000002) Business: Infectious Molecular target: D-alanyl-D-alanine Description: Second-generation glycopeptide antibiotic …

    Published on 5/5/2014
  • FX006: Phase IIb started

    Flexion Therapeutics Inc. (NASDAQ:FLXN), Burlington, Mass. Product: FX006 Business: Autoimmune Molecular target: NA Description: Sustained-release intra-articular formulation of triamcinolone acetonide Indication: Treat…

    Published on 5/5/2014
  • G-Pump: Phase II started

    Xeris Pharmaceuticals Inc., Austin, Texas Product: G-Pump (glucagon infusion) Business: Endocrine/Metabolic Molecular target: NA Description: Stable, ready-to-inject glucagon infusion Indication: Treat Type I diabetes …

    Published on 5/5/2014
  • HP-3070: Phase I started

    Hisamitsu Pharmaceutical Co. Inc. (Tokyo:4530), Tosu, Japan Product: HP-3070 Business: Neurology Molecular target: NA Description: Transdermal tape formulation of an undisclosed compound developed using Hisamitsu's …

    Published on 5/5/2014
  • NurOwn: Phase II started

    BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), New York, N.Y. Product: NurOwn (formerly Neurotrophic Factor Cells) Business: Neurology Molecular target: Not applicable Description: Autologous mesenchymal stromal cells …

    Published on 5/5/2014
  • PEG PAL: Phase III amended

    BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Novato, Calif. Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: PEG PAL, BMN 165 (formerly Phenylase) Business: Endocrine/Metabolic Molecular target: NA Description: …

    Published on 5/5/2014
  • Plecanatide: Phase III started

    Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), New York, N.Y. Product: Plecanatide (formerly SP-304, guanilib) Business: Gastrointestinal Molecular target: Guanylate cyclase C (GCC) (GUCY2C) Description: Guanylate cyclase …

    Published on 5/5/2014
  • PledOx calmangafodipir: Phase IIb ongoing

    PledPharma AB (SSE:PLED), Stockholm, Sweden Product: PledOx calmangafodipir Business: Hematology Molecular target: Superoxide dismutase 2 mitochondrial (SOD2) (MNSOD) Description: Pyridoxyl ethyldiamine (PLED) analog in…

    Published on 5/5/2014
  • Pridopidine: Phase II started

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Product: Pridopidine Business: Neurology Molecular target: Dopamine receptor Description: Dopamine stabilizer Indication: Treat symptoms of Huntington…

    Published on 5/5/2014
  • Pulmaquin liposomal ciprofloxacin: Phase III started

    Aradigm Corp. (OTCBB:ARDM), Hayward, Calif. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS), Barcelona, Spain Product: Pulmaquin liposomal ciprofloxacin (ARD-3150) Business: Pulmonary Molecular target: DNA gyrase Description: …

    Published on 5/5/2014
  • Revlimid lenalidomide: Phase III started

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Product: Revlimid lenalidomide (formerly CDC 501) Business: Cancer Molecular target: Unknown Description: Thalidomide analog Indication: Treat relapsed or refractory indolent …

    Published on 5/5/2014
  • Revlimid lenalidomide: Phase IIIb started

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Product: Revlimid lenalidomide (formerly CDC 501) Business: Cancer Molecular target: Unknown Description: Thalidomide analog Indication: Treat relapsed and/or refractory …

    Published on 5/5/2014
  • RXI-109: Phase IIa started

    RXi Pharmaceuticals Corp. (NASDAQ:RXII), Westborough, Mass. Product: RXI-109 Business: Dermatology Molecular target: Connective tissue growth factor (CTGF) Description: Self-delivering rxRNA (sd-rxRNA) compound …

    Published on 5/5/2014
  • Selinexor: Phase II started

    Karyopharm Therapeutics Inc. (NASDAQ:KPTI), Natick, Mass. Product: Selinexor (KPT-330) Business: Cancer Molecular target: Exportin 1 (XPO1) (CRM1) Description: Oral selective inhibitor of nuclear export (SINE) protein …

    Published on 5/5/2014
  • Selinexor: Phase II started

    Karyopharm Therapeutics Inc. (NASDAQ:KPTI), Natick, Mass. Product: Selinexor (KPT-330) Business: Cancer Molecular target: Exportin 1 (XPO1) (CRM1) Description: Oral selective inhibitor of nuclear export (SINE) protein …

    Published on 5/5/2014
  • Soliris eculizumab: Phase III started

    Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Cheshire, Conn. Product: Soliris eculizumab Business: Autoimmune Molecular target: Complement 5 (C5) Description: Humanized mAb targeting complement 5 (C5) Indication: Treat …

    Published on 5/5/2014
  • Soliris eculizumab: Phase III started

    Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Cheshire, Conn. Product: Soliris eculizumab Business: Autoimmune Molecular target: Complement 5 (C5) Description: Humanized mAb targeting complement 5 (C5) Indication: Treat …

    Published on 5/5/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993